Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Rock Creek Pharmaceuticals, Inc. (OTC: RCPIQ).

Full DD Report for RCPIQ

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.000550.000550.000550.00055888
2018-12-130.00050.00050.000550.00051,727
2018-12-120.00050.000520.000550.0005171,873
2018-12-110.000550.00050.000550.000512,887
2018-12-100.000350.00050.00060.0003501,172

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-131,0471,72760.6254Short
2018-12-12150,476171,87387.5507Short
2018-12-1116012,8871.2416Cover
2018-12-10148501,1720.0295Cover
2018-11-301,20011,47210.4603Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RCPIQ.


About Rock Creek Pharmaceuticals, Inc. (OTC: RCPIQ)

Logo for Rock Creek Pharmaceuticals, Inc. (OTC: RCPIQ)

Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases.

 

 

 

Current Management

  • Michael J. Mullan / CEO
    • Dr. Mullan is a global leader in medical research. From until the present, Dr. Mullan served as Chief Executive Officer and President of the Roskamp Institute, an independent biomedical research establishment in Sarasota, Florida. He most recently served as Chief Executive Officer of Archer Pharmaceuticals, Inc., which under his direction advanced a drug to Phase III clinical trials for Alzheimer s Disease in Europe. Dr. Mullan trained first as a physician specializing in the assessment and treatment of Alzheimer s Disease. He was one of the first to discover the genetic causes of Alzheimer s Disease and is the inventor of numerous patents related to Alzheimer s Disease causes and treatments. Dr. Mullan has coauthored more than research papers on the causes including the role of inflammation and treatments of neurological disorders. Dr. Mullan received his medical degree, MBBS, and Ph.D. in Molecular Genetics from London University.
  • William McMahon / Interim CFO
    • Prior to be engaged by the Company in July , Mr. McMahon, age , served at the Chief Financial Officer for Neptune Minerals, Inc., a company engaged in deep ocean minerals exploration and resource development. Mr. McMahon joined Neptune Minerals in January after serving as an interim CFO while as a partner in Tatum LLC, a firm specializing in interim CFO positions, and continues to serve as Neptune s Chief Financial Officer on a parttime basis. Prior to Neptune, from January to January Mr. McMahon served as a Partner of Tatum LLC, where he was responsible for interim CFO positions for clients of Tatum. From January to January , Mr. McMahon as an independent contractor providing financial management consulting services to privately held manufacturing clients. During the course of his career, Mr. McMahon has participated in raising equity and debt capital, working with senior lenders and private equity partners. During his plus year career, Mr. McMahon has also served as Chief Financial Officer, Controller and Treasurer for various small to medium size public and private companies. Mr. McMahon has a diverse industry background working in manufacturing, distribution, transportation and logistics, retail and hospitality as well as defense, high tech and wireless communication. Mr. McMahon holds a Bachelor of Science in Accounting degree from DePaul University in Chicago, Illinois.
  • Theodore Jenkins / VP, Corp. Dev., IR, Corporate Secretary
    • Mr Jenkins is an year Wall Street institutional capital markets professional, working at Alex. Brown amp Sons, Salomon Brothers, Credit Suisse First Boston, Friedman, Billings Ramsey and Oppenheimer amp Co. He brings valuable insight, aptitude and knowledge across a wide spectrum of biotech specific and pharmaceutical healthcare disciplines, and has an abundance of relationships across the institutional and corporate banking investment community. Mr Jenkins spent an additional years as a US Navy Officer where he served as an aviator, flying F a tactical fighter aircraft, finishing up his tour as a professional development instructor, teaching midshipmen at the US Naval Academy in Annapolis, Maryland. He has a Master s of Science in Business from The John s Hopkins University, and an undergraduate degree in International Studies from Washington College in Chestertown, Maryland.
  • Michael J. Mullan / Chairman
    • Dr. Mullan is a global leader in medical research. From until the present, Dr. Mullan served as Chief Executive Officer and President of the Roskamp Institute, an independent biomedical research establishment in Sarasota, Florida. He most recently served as Chief Executive Officer of Archer Pharmaceuticals, Inc., which under his direction advanced a drug to Phase III clinical trials for Alzheimer s Disease in Europe. Dr. Mullan trained first as a physician specializing in the assessment and treatment of Alzheimer s Disease. He was one of the first to discover the genetic causes of Alzheimer s Disease and is the inventor of numerous patents related to Alzheimer s Disease causes and treatments. Dr. Mullan has coauthored more than research papers on the causes including the role of inflammation and treatments of neurological disorders. Dr. Mullan received his medical degree, MBBS, and Ph.D. in Molecular Genetics from London University.
  • Lee Canaan / Director
    • Ms. Lee Musgrove Canaan brings twentyfive years of financial and public capital markets experience and thirtyfive years of scientific and technical expertise to our board. She has working knowledge of both debt and equity markets as an institutional investor and a corporate finance professional and has served on the board of several publiclytraded companies. Currently Ms. Canaan is the portfolio manager of a private money management firm she founded in . Prior to that, she was a fixed income analyst for the high yield debt team at AIM Management part of the Invesco Family of funds after making the transition from corporate finance professional in the treasury operations of ARCO, a Fortune energy company. Ms. Canaan started her career as a geophysicist at AMOCO. She also has private market investment experience and was recognized by the U.S. Department of Energy as a financial and technical expert for the purposes of evaluating government investments in the renewable energy space. Ms. Canaan has a B.S. in Geological Sciences from the University of Southern California, a Masters in Geophysics from the University of Texas at Austin, and an M.B.A. in Finance from the Wharton School at the University of Pennsylvania. She holds the Chartered Financial Analyst CFA designation. Ms. Canaan resides in Ann Arbor, MI.
  • Robert Scannell / Director
    • Mr. Scannell was cofounder and General Partner of IASO Advisors, LLC, an investment firm focused on healthcare and biotech based in San Francisco, California. Previously, he spent years as the founder and General Partner of Tradewinds Investment Management. Mr. Scannell holds a Juris Doctorate from Concord Law School, Los Angeles, CA, and an MBA From Penn State University. He also holds the designation as a Chartered Financial Analyst CFA .

Current Share Structure

  • Market Cap: $102,267 - 03/15/2018
  • Authorized: 314,800,000 - 03/24/2016
  • Issue and Outstanding: 170,444,758 - 08/03/2016

 



Daily Technical Chart for (OTC: RCPIQ)

Daily Technical Chart for (OTC: RCPIQ)


Stay tuned for daily updates and more on (OTC: RCPIQ)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RCPIQ)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RCPIQ is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RCPIQ and does not buy, sell, or trade any shares of RCPIQ. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/